United Therapeutics reported second quarter results that modestly exceeded Wall Street’s revenue and adjusted EPS expectations, with management highlighting the impact of competitive dynamics in the inhaled prostacyclin market. CEO Dr. Martine Rothblatt emphasized progress in the company’s clinical programs, particularly the ADVANCE OUTCOMES study for ralinepag and the TETON-1 trial for Tyvaso in pulmonary fibrosis. President Michael Benkowitz noted that although revenue was flat sequentially, operational momentum improved, driven by record patient metrics and recent sales force expansion. Management acknowledged that more time is needed for the benefits of differentiated therapies to become evident to physicians.

Is now the time to buy UTHR? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From United Therapeutics’s Q2 Earnings Call

• Joseph Thome (TD Cowen) asked about regaining momentum amid increased competition. President Michael Benkowitz described ralinepag and SMI as differentiated offerings expected to stand out due to clinical benefit and patient preference.
• Jiale Song (Jefferies) requested details on the launch trajectory for new products. Benkowitz reiterated multibillion-dollar potential but said specifics depend on regulatory timing, with more information expected later this year.
• Jessica Fye (JPMorgan) questioned the achievability of consensus Tyvaso revenue targets for the second half. Benkowitz declined to reaffirm or update guidance, only stating that performance should improve relative to the first half.
• Ryan Mcelroy (Leerink Partners) inquired about Tyvaso’s future positioning in IPF and the drivers for adopting different formulations. Benkowitz explained that polytherapy is becoming standard in IPF, with Tyvaso likely used in combination with other treatments.
• Benjamin Burnett (Wells Fargo) asked about data requirements for expanding Tyvaso DPI and SMI into IPF. EVP Leigh Peterson said discussions are ongoing with the FDA, with bridging strategies under consideration and details to be presented at future conferences.

Catalysts in Upcoming Quarters

In the coming quarters, StockStory analysts will be watching (1) progress on regulatory review and potential approval timelines for ralinepag and nebulized Tyvaso in new indications, (2) the impact of the expanded sales force on commercial performance and physician adoption, and (3) updates on clinical trial milestones, especially the TETON-PPF readout. Execution in organ transplantation and integration of Thymmune Therapeutics will also be important markers of long-term strategy.

United Therapeutics currently trades at $515, in line with $518.68 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.